Patents by Inventor David R. Corey

David R. Corey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF FUCHS' ENDOTHELIAL CORNEAL DYSTROPHY
    Publication number: 20240002849
    Abstract: Described are compounds and methods useful in the treatment of Fuchs' Endothelial Corneal Dystrophy (FECD).
    Type: Application
    Filed: November 8, 2022
    Publication date: January 4, 2024
    Applicants: The Board of Regents of The University of Texas System, University of Massachusetts
    Inventors: Venkateswara V. MOOTHA, David R. COREY, Jiaxin HU, Jonathan K. WATTS
  • Treatment of Fuchs' endothelial corneal dystrophy
    Patent number: 11512312
    Abstract: Described are compounds and methods useful in the treatment of Fuchs' Endothelial Corneal Dystrophy (FECD).
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: November 29, 2022
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Venkateswara V. Mootha, David R. Corey, Jiaxin Hu
  • MOLECULAR BIOMARKERS AND TARGETS FOR FUCHES' ENDOTHELIAL CORNEAL DYSTROPHY AND GLAUCOMA
    Publication number: 20210348234
    Abstract: Molecular biomarkers relating to Fuchs' endothelial corneal dystrophy (FECD), glaucoma, and other degenerative ocular diseases are provided, as well as methods for using such biomarkers methods of treatment. These biomarkers may be used to monitor the progression of FECD, glaucoma, or other degenerative ocular diseases. Furthermore, these biomarkers may be used to monitor the treatment of FECD, glaucoma, or other degenerative ocular diseases.
    Type: Application
    Filed: February 24, 2021
    Publication date: November 11, 2021
    Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Venkateswara Vinod MOOTHA, David R. COREY, Jiaxin HU, Yongjun CHU
  • TREATMENT OF FUCHS' ENDOTHELIAL CORNEAL DYSTROPHY
    Publication number: 20210139894
    Abstract: Described are compounds and methods useful in the treatment of Fuchs' Endothelial Corneal Dystrophy (FECD).
    Type: Application
    Filed: March 9, 2018
    Publication date: May 13, 2021
    Applicants: The Board of Regents of the University of Texas System, University of Massachusetts
    Inventors: Venkateswara V. MOOTHA, David R. COREY, Jiaxin HU, Jonathan K. WATTS
  • Selective inhibition of polyglutamine protein expression
    Patent number: 9574191
    Abstract: The present invention relates to the selective inhibition of protein expression of CAG repeat-related disease proteins such as Huntingtin Disease Protein and Ataxin-3 using double-stranded RNAs and nucleic acid analogs. Chemically-modified RNAs having at least one mismatch as compared to the target CAG repeat sequence are specifically contemplated.
    Type: Grant
    Filed: February 3, 2011
    Date of Patent: February 21, 2017
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: David R. Corey, Jiaxin Hu, Dinah W. Y. Sah
  • Selective inhibition of polyglutamine protein expression
    Patent number: 9340785
    Abstract: The present invention relates to the selective inhibition of protein expression of CAG repeat-related disease proteins such as Huntington using nucleic acid analogs. Peptide nucleic acids and locked nucleic acids are particularly useful analogs.
    Type: Grant
    Filed: November 3, 2014
    Date of Patent: May 17, 2016
    Assignee: The Board of Regents of the University of Texas System
    Inventors: David R. Corey, Jiaxin Hu, Masayuki Matsui
  • SELECTIVE INHIBITION OF POLYGLUTAMINE PROTEIN EXPRESSION
    Publication number: 20150211007
    Abstract: The present invention relates to the selective inhibition of protein expression of CAG repeat-related disease proteins such as Huntington using nucleic acid analogs. Peptide nucleic acids and locked nucleic acids are particularly useful analogs.
    Type: Application
    Filed: November 3, 2014
    Publication date: July 30, 2015
    Applicant: The Board of Regents of the University of Texas System
    Inventors: David R. COREY, Jiaxin HU, Masayuki MATSUI
  • MODULATING GENE EXPRESSION WITH agRNA AND GAPMERS TARGETING ANTISENSE TRANSCRIPTS
    Publication number: 20150064709
    Abstract: Gene expression is selectively modulated in the genome of a mammalian cell determined to be in need thereof by determining the presence of an encoded antisense transcript overlapping a promoter of the target gene; contacting the transcript with an agRNA or gapmer complementary to a portion of the transcript upstream relative to the transcription start site of the gene; and detecting a resultant modulation of expression of the target gene.
    Type: Application
    Filed: September 10, 2014
    Publication date: March 5, 2015
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Jacob C. SCHWARTZ, Scott T. YOUNGER, Bethany A. JANOWSKI, David R. COREY
  • Selective inhibition of polyglutamine protein expression
    Patent number: 8901095
    Abstract: The present invention relates to the selective inhibition of protein expression of CAG repeat-related disease proteins such as Huntingtin using nucleic acid analogs. Peptide nucleic acids and locked nucleic acids are particularly useful analogs.
    Type: Grant
    Filed: July 28, 2009
    Date of Patent: December 2, 2014
    Assignee: The Board of Regents of the University of Texas System
    Inventors: David R. Corey, Jiaxin Hu, Masayuki Matsui
  • Modulation of gene expression using oligomers that target gene regions downstream of 3? untranslated regions
    Patent number: 8815586
    Abstract: Gene expression can be selectively modulated by contacting a cell with an oligomer that targets a gene region downstream of a ?3-UTR, thereby increasing or decreasing the expression of the target gene.
    Type: Grant
    Filed: April 23, 2010
    Date of Patent: August 26, 2014
    Assignee: The Board of Regents of the University of Texas System
    Inventors: David R. Corey, Xuan Yue
  • OLIGONUCLEOTIDE MODULATION OF SPLICING
    Publication number: 20140128449
    Abstract: The present invention relates to the selective modulation of pre-mRNA splicing, in particular, for that involving alternative splicing in disease-related proteins such as those involved in Duschenne's Muscular Dystropy and Spinal Muscular Atrophy.
    Type: Application
    Filed: March 23, 2012
    Publication date: May 8, 2014
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Jing Liu, Jiaxin Hu, David R. Corey
  • SELECTIVE INHIBITION OF POLYGLUTAMINE PROTEIN EXPRESSION
    Publication number: 20130172399
    Abstract: The present invention relates to the selective inhibition of protein expression of CAG repeat-related disease proteins such as Huntingtin Disease Protein and Ataxin-3 using double-stranded RNAs and nucleic acid analogs. Chemically-modified RNAs having at least one mismatch as compared to the target CAG repeat sequence are specifically contemplated.
    Type: Application
    Filed: February 3, 2011
    Publication date: July 4, 2013
    Inventors: David R. Corey, Jiaxin Hu, Dinah W.Y. Sah
  • Modulation of gene expression by oligomers targeted to chromosomal DNA
    Patent number: 8324181
    Abstract: Synthesis of a target transcript of a gene is selectively increased in a mammalian cell by contacting the cell with a polynucleotide oligomer of 12-28 bases complementary to a region within a target promoter of the gene under conditions whereby the oligomer selectively increases synthesis of the target transcript.
    Type: Grant
    Filed: March 30, 2010
    Date of Patent: December 4, 2012
    Assignee: Board of Regents, The University of Texas System
    Inventors: David R. Corey, David S. Shames, Bethany A. Janowski, John D. Minna
  • Modulating Gene Expression With agRNA and Gapmers Targeting Antisense Transcripts
    Publication number: 20120288869
    Abstract: Gene expression is selectively modulated in the genome of a mammalian cell determined to be in need thereof by determining the presence of an encoded antisense transcript overlapping a promoter of the target gene; contacting the transcript with an agRNA or gapmer complementary to a portion of the transcript upstream relative to the transcription start site of the gene; and detecting a resultant modulation of expression of the target gene.
    Type: Application
    Filed: July 3, 2012
    Publication date: November 15, 2012
    Inventors: Jacob C. Schwartz, Scott T. Younger, Bethany A. Janowski, David R. Corey
  • Modulation of gene expression through endogenous small RNA targeting of gene promoters
    Patent number: 8222221
    Abstract: Gene expression can be selectively regulated by endogenous miRNAs that target promoters of genes. Altering of the activity of these promoter-targeting miRNAs with single-stranded complementary oligonucleotides that bind the miRNA causes modulation of expression of the target gene. Endogenous miRNAs that modulate expression of target genes can be identified by (a) evaluating an endogenous miRNA for complementarity to a target gene promoter; and (b) determining that the complementary miRNA modulates expression of the target gene.
    Type: Grant
    Filed: June 3, 2009
    Date of Patent: July 17, 2012
    Assignee: The Board of Regents of the University of Texas System
    Inventors: David R. Corey, Scott T. Younger
  • Selective Inhibition of Polyglutamine Protein Expression
    Publication number: 20110190222
    Abstract: The present invention relates to the selective inhibition of protein expression of CAG repeat-related disease proteins such as Huntingtin using nucleic acid analogs. Peptide nucleic acids and locked nucleic acids are particularly useful analogs.
    Type: Application
    Filed: July 28, 2009
    Publication date: August 4, 2011
    Inventors: David R. Corey, Jiaxin Hu, Masayuki Matsui
  • MODULATION OF LDL RECEPTOR GENE EXPRESSION WITH DOUBLE-STRANDED RNAS TARGETING THE LDL RECEPTOR GENE PROMOTER
    Publication number: 20110110860
    Abstract: Gene expression can be selectively regulated by double-stranded “antigene” RNAs that target regions of the low density lipoprotein receptor (LDL-R) promoter, thereby permitting modulation of LDL levels in vivo and subsequent effects on circulating LDL levels.
    Type: Application
    Filed: November 2, 2010
    Publication date: May 12, 2011
    Applicants: The Board of Regents of the University of Texas System, Alnylam Pharmaceuticals Inc.
    Inventors: DAVID R. COREY, Masayuki Matsui, Muthiah Manoharan, Sayda Elbashir
  • Interfering RNAs against the promoter region of P53
    Patent number: 7858592
    Abstract: The present invention relates to the inhibition of p53 transcription by interfering with the activity of a p53 promoter using inhibitory double-stranded RNAs. Use of these inhibitory RNAs in the treatment of cancers also is disclosed.
    Type: Grant
    Filed: February 22, 2008
    Date of Patent: December 28, 2010
    Assignee: The Board of Regents of the University of Texas System
    Inventors: David S. Shames, David R. Corey, Rachel S. Greer, John D. Minna
  • Modulation of Gene Expression Using Oligomers That Target Gene Regions Downstream of 3' Untranslated Regions
    Publication number: 20100273863
    Abstract: Gene expression can be selectively modulated by contacting a cell with an oligomer that targets a gene region downstream of a ?3-UTR, thereby increasing or decreasing the expression of the target gene.
    Type: Application
    Filed: April 23, 2010
    Publication date: October 28, 2010
    Inventors: David R. Corey, Xuan Yue
  • Modulation of gene expression by oligomers targeted to chromosomal DNA
    Patent number: 7709456
    Abstract: Synthesis of a target transcript of a gene is selectively increased in a mammalian cell by contacting the cell with a polynucleotide oligomer of 12-28 bases complementary to a region within a target promoter of the gene under conditions whereby the oligomer selectively increases synthesis of the target transcript.
    Type: Grant
    Filed: November 13, 2006
    Date of Patent: May 4, 2010
    Assignee: Board of Regents, The University of Texas System
    Inventors: David R. Corey, David S. Shames, Bethany A. Janowski, John D. Minna